Combination Therapy of a PD-1 Antagonist and an Antagonist for VEGFR-2 for Treating Patients with Cancer
AssigneesPharmabcine Inc., Merck Sharp & Dohme Corp., MSD International GmbH
InventorsSeon Young Lee, Weon Sup Lee, Jin-San Yoo, Sang Ryeol Shim
Life of this patent
Estimating the term…
Abstract
The present disclosure describes combination therapies comprising an antagonist of Programmed cell Death 1 receptor (PD-1) and a vascular endothelial growth factor receptor-2 (VEGFR-2) antagonist, and the use of the combination therapies for the treatment of a cancer. In an embodiment, the cancer is a glioblastoma, a breast cancer, a triple negative breast cancer, a metastatic breast cancer, or a metastatic triple negative breast cancer.
Claims26
A method for treating a cancer in an individual comprising administering to the individual a PD-1 antagonist and a VEGFR-2 antagonist.
Dependencies are inferred from the claim text.